Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma

PURPOSE: Bevacizumab treatment at 7.5 mg/kg every 3 weeks results in improved hearing in approximately 35%-40% of patients with neurofibromatosis type 2 (NF2) and progressive vestibular schwannomas (VSs). However, the optimal dose is unknown. In this multicenter phase II and biomarker study, we eval...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Oncol
Hlavní autoři: Plotkin, Scott R., Duda, Dan G., Muzikansky, Alona, Allen, Jeffrey, Blakeley, Jaishri, Rosser, Tena, Campian, Jian L., Clapp, D. Wade, Fisher, Michael J., Tonsgard, James, Ullrich, Nicole, Thomas, Coretta, Cutter, Gary, Korf, Bruce, Packer, Roger, Karajannis, Matthias A.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2019
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7098833/
https://ncbi.nlm.nih.gov/pubmed/31626572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01367
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky